OS Therapies (NYSEAMERICAN:OSTX) Shares Down 2.5% – Time to Sell?

Shares of OS Therapies Incorporated (NYSEAMERICAN:OSTX) were down 2.5% during mid-day trading on Monday . The company traded as low as $1.4602 and last traded at $1.55. 438,582 shares changed hands during trading, an increase of 34% from the average daily volume of 328,382 shares. The stock had previously closed at $1.59.

Wall Street Analyst Weigh In

OSTX has been the subject of a number of analyst reports. Lake Street Capital cut their price target on OS Therapies from $14.00 to $13.00 and set a “buy” rating for the company in a report on Tuesday, May 19th. Zacks Research upgraded OS Therapies from a “strong sell” rating to a “hold” rating in a research note on Thursday, June 4th. Roth Capital assumed coverage on OS Therapies in a report on Thursday, July 9th. They set a “buy” rating and a $7.00 price objective on the stock. Finally, D. Boral Capital restated a “buy” rating and issued a $20.00 target price on shares of OS Therapies in a research note on Thursday, April 30th. Three analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $13.33.

OS Therapies Price Performance

The firm’s 50 day moving average is $1.65 and its 200 day moving average is $1.58. The company has a market cap of $75.42 million, a PE ratio of -1.50 and a beta of -0.73.

OS Therapies (NYSEAMERICAN:OSTX) last posted its earnings results on Friday, August 14th. The company reported ($0.20) earnings per share (EPS) for the quarter. As a group, analysts anticipate that OS Therapies Incorporated will post -0.77 EPS for the current year.

Institutional Investors Weigh In On OS Therapies

Institutional investors and hedge funds have recently made changes to their positions in the business. AXQ Capital LP purchased a new position in OS Therapies during the second quarter worth about $47,000. State Street Corp raised its holdings in shares of OS Therapies by 16.3% in the 4th quarter. State Street Corp now owns 58,500 shares of the company’s stock valued at $82,000 after acquiring an additional 8,200 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of OS Therapies in the 4th quarter valued at about $39,000. Geode Capital Management LLC boosted its position in shares of OS Therapies by 31.1% during the 4th quarter. Geode Capital Management LLC now owns 246,038 shares of the company’s stock valued at $344,000 after acquiring an additional 58,350 shares during the last quarter. Finally, Susquehanna International Group LLP bought a new stake in shares of OS Therapies during the 3rd quarter valued at about $29,000.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.